Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
暂无分享,去创建一个
L. Senter | D. Cohn | F. Backes | D. O’Malley | L. Copeland | C. Cosgrove | K. Bixel | M. Levine | V. Wagner | Paulina J Haight | Eric M. McLaughlin